Delivery Order SPE2DB24D9238-SPE2DB26FDQEA
- Not listed
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $34,224.40 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EYLEA 2 mg/0.05 mL syringes. The award was issued on October 27, 2025, with an ultimate completion date of November 18, 2025, and carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This...
- The U.S. Defense Logistics Agency (DLA), operating under the Medical Supply Chain, awarded a $29,335.20 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The delivery order, issued July 7, 2025 with completion targeted for July 28, 2025, covers the supply of EYLEA 2 mg/0.05 mL syringes. This award was made without set-aside designation, leveraging the vendor's competitive positioning as a...
- The Defense Logistics Agency awarded a $2,513.56 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Eylea 2 mg/0.05 ml vials. The delivery order, issued on September 3, 2025, with an ultimate completion date of September 24, 2025, represents a specialized pharmaceutical procurement under DLA's broader pharmaceutical supply mission. This award carries no set-aside designation,...
- The U.S. Defense Logistics Agency (DLA) awarded a $3,940.44 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The delivery order, which has a completion date of July 18, 2024, is for the supply of EYLEA 2 MG/0.05 ML VIAL 0.05ML, a pharmaceutical product used to treat certain medical conditions. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to...
- The U.S. government's Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $5,253.92 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of EYLEA 2 MG/0.05 ML VIAL 0.05ML, a pharmaceutical product, with a completion date of August 27, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group Inc. valued at up to...
- The Defense Logistics Agency awarded a delivery order valued at $12,567.70 to DMS Pharmaceutical Group Inc. for the supply of EYLEA (2 mg/0.05 mL vials). The award, issued on June 2, 2025, with an ultimate completion date of June 24, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. This order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA valued at approximately $500 million through November 2026, which...
- The Defense Logistics Agency awarded a $20,220 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EYLEA HD 8 mg/0.07 mL vials. The delivery order, issued on October 27, 2025, with an ultimate completion date of November 18, 2025, contains no set-aside designation, indicating the award was made through competitive procurement. DMS Pharmaceutical Group Inc. will serve as the...
- The Defense Logistics Agency (DLA) awarded a $79.25K firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EYLEA HD 8 mg/0.07 ml vials. The delivery order, issued on July 15, 2025, with an ultimate completion date of August 5, 2025, was awarded without a set-aside designation. This award is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency (DLA) awarded a $5,943.78 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EYLEA HD 8 mg/0.07 ml vial medication. This delivery order, issued on September 5, 2025, with an ultimate completion date of September 26, 2025, carries no set-aside designation. DMS Pharmaceutical Group is performing at its Park Ridge facility and will deliver this...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $6,283.85 by the Defense Logistics Agency on August 29, 2025, for the supply of EYLEA 2 mg/0.05 ml vials. The contract utilizes firm fixed-price pricing with an ultimate completion date of September 22, 2025, and carries no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger single-award Indefinite...
- SPE2DB24D9238Indefinite Delivery Contract
- SPE2DB24D9238-SPE2DB26FDQEADelivery Order
The Defense Logistics Agency (DLA) issued a delivery order valued at $5,027.08 to DMS Pharmaceutical Group Inc. for EYLEA 2 mg/0.05 mL vials on October 29, 2025, with completion scheduled for November 20, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected under a firm fixed-price contract structure with no set-aside designation. This delivery order represents one of numerous purchases issued to the company by DLA's Medical Supply Chain division during October 2025, reflecting the contractor's established capacity to supply specialized pharmaceutical products to federal agencies. This award falls under DMS Pharmaceutical Group's broader single-award Indefinite Delivery Contract (IDC) with DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that establishes multiple regional prime vendor contractors. DMS Pharmaceutical Group's PPV-G GEN V contract, valued at $499,999,999 and effective through December 31, 2036, authorizes the company to supply branded and generic prescription medications, biologics, and medical consumables to support Department of Defense military healthcare facilities worldwide. The company demonstrates substantial federal contracting experience across diverse pharmaceutical categories and has performed consistently on delivery orders ranging from minimal to six-figure values, establishing it as a critical supplier within the federal pharmaceutical supply chain for military medical operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.0k | 10/29/25 |